All lobbying filings

FORBES-TATE

Lobbying for AMGEN USA, INC. · Biotech company that discovers, develops, manufactures and delivers human theraputics

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $80,000.00 income · posted Apr 17, 2026

Official filing document

Lobbying activity 4

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medical/Disease Research/Clinical Labs

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Budget/Appropriations

Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Taxation/Internal Revenue Code

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.